Death receptor 6 (DR6) antagonist antibody is neuroprotective in the mouse SOD1G93A model of amyotrophic lateral sclerosis

Cell Death and Disease

Volumn 4, Issue 10, 2013, Pages

  Huang, G ^a   Lee, X ^a   Bian, Y ^a   Shao, Z ^a   Sheng, G ^a   Pepinsky, R B ^a   Mi, S ^a  

^a BIOGEN   (United States)

Author keywords

ALS; DR6; Motor neuron; Neurodegeneration; Neurofilament; NMJ

Indexed keywords

ARSENITE SODIUM; CASPASE 3; DEATH RECEPTOR; DEATH RECEPTOR 6; DEATH RECEPTOR 6 ANTAGONIST ANTIBODY 5D10; NEUROFILAMENT PROTEIN; NEUROPROTECTIVE AGENT; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; CELL SURVIVAL; CERVICAL SPINAL CORD; CONTROLLED STUDY; DENERVATION; ENZYME ACTIVATION; GLIOSIS; GRIP STRENGTH; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MOTONEURON; MOTOR PERFORMANCE; MOUSE; NERVE CELL NECROSIS; NERVE FIBER DEGENERATION; NEUROFILAMENT; NEUROMUSCULAR SYNAPSE; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION;

AMINO ACID SUBSTITUTION; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTIBODIES, BLOCKING; AXONS; CASPASE 3; CELL SURVIVAL; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; MOTOR NEURONS; NEUROPROTECTIVE AGENTS; PHOSPHORYLATION; POSTMORTEM CHANGES; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RECEPTORS, TUMOR NECROSIS FACTOR; RNA, MESSENGER; SPINAL CORD; SUPEROXIDE DISMUTASE; UP-REGULATION;

EID: 84887496713     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.378     Document Type: Article

References (60)

1. Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: Deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001; 2: 806-819
2. Andersen PM, Al-Chalabi A. Clinical genetics of amyotrophic lateral sclerosis: What do we really know? Nat Rev Neurol 2011; 7: 603-615
3. Johnston CA, Stanton BR, Turner MR, Gray R, Blunt AH, Butt D et al. Amyotrophic lateral sclerosis in an urban setting: A population based study of inner city London. J Neurol 2006; 253: 1642-1643
4. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59-62
5. Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008; 319: 1668-1672
6. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011; 72: 245-256
7. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009; 323: 1205-1208
8. Greenway MJ, Andersen PM, Russ C, Ennis S, Cashman S, Donaghy C et al. ANG mutations segregate with familial and sporadic amyotrophic lateral sclerosis. Nat Genet 2006; 38: 411-413
9. Nishimura AL, Mitne-Neto M, Silva HC, Richieri-Costa A, Middleton S, Cascio D et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet 2004; 75: 822-831
10. Kiaei M, Petri S, Kipiani K, Gardian G, Choi DK, Chen J et al. Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 2006; 26: 2467-2473
11. Stommel EW, Cohen JA, Fadul CE, Cogbill CH, Graber DJ, Kingman L et al. Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: A phase II open label clinical trial. Amyotroph Lateral Scler 2009; 10: 393-404
12. Bordet T, Buisson B, Michaud M, Drouot C, Galea P, Delaage P et al. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther 2007; 322: 709-720
13. Danzeisen R, Schwalenstoecker B, Gillardon F, Buerger E, Krzykalla V, Klinder K et al. Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6, 7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride]. J Pharmacol Exp Ther 2006; 316: 189-199
14. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994; 264: 1772-1775
15. Tu PH, Raju P, Robinson KA, Gurney ME, Trojanowski JQ, Lee VM. Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions. Proc Natl Acad Sci USA 1996; 93: 3155-3160
16. Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-Sanchez A et al. Amyotrophic lateral sclerosis is a distal axonopathy: Evidence in mice and man. Exp Neurol 2004; 185: 232-240
17. Hall ED, Oostveen JA, Gurney ME. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 1998; 23: 249-256
18. Pasinelli P, Houseweart MK, Brown RH Jr., Cleveland DW. Caspase-1 and -3 are sequentially activated in motor neuron death in Cu,Zn superoxide dismutasemediated familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2000; 97: 13901-13906
19. Li M, Ona VO, Guegan C, Chen M, Jackson-Lewis V, Andrews LJ et al. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 2000; 288: 335-339
20. Boylan K, Yang C, Crook J, Overstreet K, Heckman M, Wang Y et al. Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: Evaluation of blood pNF-H as a potential ALS biomarker. J Neurochem 2009; 111: 1182-1191
21. Petzold A, Keir G, Green AJ, Giovannoni G, Thompson EJ. A specific ELISA for measuring neurofilament heavy chain phosphoforms. J Immunol Methods 2003; 278: 179-190
22. Ganesalingam J, An J, Bowser R, Andersen PM, Shaw CE. pNfH is a promising biomarker for ALS. Amyotroph Lateral Scler Frontotemporal Degener 2013; 14: 146-149
23. Siegel RM. Caspases at the crossroads of immune-cell life and death. Nat Rev Immunol 2006; 6: 308-317
24. Lavrik I, Golks A, Krammer PH. Death receptor signaling. J Cell Sci 2005; 118(Pt 2): 265-267
25. Nikolaev A, McLaughlin T, OLeary DD, Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 2009; 457: 981-989
26. Hu Y, Lee X, Shao Z, Apicco D, Huang G, Gong BJ et al. A DR6/p75(NTR) complex is responsible for beta-amyloid-induced cortical neuron death. Cell Death Dis 2013; 4: E579
27. Mi S, Lee X, Hu Y, Ji B, Shao Z, Yang W et al. Death receptor 6 negatively regulates oligodendrocyte survival, maturation and myelination. Nat Med 2011; 17: 816-821
28. Lee Y, Morrison BM, Li Y, Lengacher S, Farah MH, Hoffman PN et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature 2012; 487: 443-448
29. Kang SH, Li Y, Fukaya M, Lorenzini I, Cleveland DW, Ostrow LW et al. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic lateral sclerosis. Nat Neurosci 2013; 16: 571-579
30. Philips T, Bento-Abreu A, Nonneman A, Haeck W, Staats K, Geelen V et al. Oligodendrocyte dysfunction in the pathogenesis of amyotrophic lateral sclerosis. Brain 2013; 136(Pt 2): 471-482
31. Haidet-Phillips AM, Hester ME, Miranda CJ, Meyer K, Braun L, Frakes A et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol 2011; 29: 824-828
32. Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, Wichterle H et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 2007; 10: 615-622
33. Kilinc D, Gallo G, Barbee KA. Mechanically-induced membrane poration causes axonal beading and localized cytoskeletal damage. Exp Neurol 2008; 212: 422-430
34. Shobha K, Vijayalakshmi K, Alladi PA, Nalini A, Sathyaprabha TN, Raju TR. Altered in-vitro and in-vivo expression of glial glutamate transporter-1 following exposure to cerebrospinal fluid of amyotrophic lateral sclerosis patients. J Neurol Sci 2007; 254: 9-16
35. Fernandes-Alnemri T, Litwack G, Alnemri ES. CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem 1994; 269: 30761-30764
36. Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 1997; 275: 661-665
37. Martorana F, Brambilla L, Valori CF, Bergamaschi C, Roncoroni C, Aronica E et al. The BH4 domain of Bcl-X(L) rescues astrocyte degeneration in amyotrophic lateral sclerosis by modulating intracellular calcium signals. Hum Mol Genet 2012; 21: 826-840
38. Rossi D, Brambilla L, Valori CF, Roncoroni C, Crugnola A, Yokota T et al. Focal degeneration of astrocytes in amyotrophic lateral sclerosis. Cell Death Differ 2008; 15: 1691-1700
39. Scott S, Kranz JE, Cole J, Lincecum JM, Thompson K, Kelly N et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler 2008; 9: 4-15
40. Rouaux C, Panteleeva I, Rene F, Gonzalez de Aguilar JL, Echaniz-Laguna A, Dupuis L et al. Sodium valproate exerts neuroprotective effects in vivo through CREB-binding proteindependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model. J Neurosci 2007; 27: 5535-5545
41. Da Cruz S, Parone PA, Lopes VS, Lillo C, McAlonis-Downes M, Lee SK et al. Elevated PGC-1alpha activity sustains mitochondrial biogenesis and muscle function without extending survival in a mouse model of inherited ALS. Cell Metabol 2012; 15: 778-786
42. Kariya S, Re DB, Jacquier A, Nelson K, Przedborski S, Monani UR. Mutant superoxide dismutase 1 (SOD1), a cause of amyotrophic lateral sclerosis, disrupts the recruitment of SMN, the spinal muscular atrophy protein to nuclear Cajal bodies. Human Mol Genet 2012; 21: 3421-3434
43. Tesla R, Wolf HP, Xu P, Drawbridge J, Estill SJ, Huntington P et al. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2012; 109: 17016-17021
44. Barker PA. p75NTR is positively promiscuous: Novel partners and new insights. Neuron 2004; 42: 529-533
45. Bibel M, Hoppe E, Barde YA. Biochemical and functional interactions between the neurotrophin receptors trk and p75NTR. EMBO J 1999; 18: 616-622
46. Nykjaer A, Lee R, Teng KK, Jansen P, Madsen P, Nielsen MS et al. Sortilin is essential for proNGF-induced neuronal cell death. Nature 2004; 427: 843-848
47. Mi S, Lee X, Shao Z, Thill G, Ji B, Relton J et al. LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex. Nat Neurosci 2004; 7: 221-228
48. Lowry KS, Murray SS, McLean CA, Talman P, Mathers S, Lopes EC et al. A potential role for the p75 low-affinity neurotrophin receptor in spinal motor neuron degeneration in murine and human amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2001; 2: 127-134
49. Turner BJ, Ackerley S, Davies KE, Talbot K. Dismutase-competent SOD1 mutant accumulation in myelinating Schwann cells is not detrimental to normal or transgenic ALS model mice. Hum Mol Genet 2010; 19: 815-824
50. Lino MM, Schneider C, Caroni P. Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. J Neurosci 2002; 22: 4825-4832
51. Turner BJ, Cheah IK, Macfarlane KJ, Lopes EC, Petratos S, Langford SJ et al. Antisense peptide nucleic acid-mediated knockdown of the p75 neurotrophin receptor delays motor neuron disease in mutant SOD1 transgenic mice. J Neurochem 2003; 87: 752-763
52. Kust BM, Brouwer N, Mantingh IJ, Boddeke HW, Copray JC. Reduced p75NTR expression delays disease onset only in female mice of a transgenic model of familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2003; 4: 100-105
53. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001; 344: 1688-1700
54. Ferraiuolo L, Kirby J, Grierson AJ, Sendtner M, Shaw PJ. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol 2011; 7: 616-630
55. Turner BJ, Talbot K. Transgenics toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog Neurobiol 2008; 85: 94-134
56. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994; 330: 585-591
57. Mi S, Miller RH, Lee X, Scott ML, Shulag-Morskaya S, Shao Z et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci 2005; 8: 745-751
58. Gingras M, Gagnon V, Minotti S, Durham HD, Berthod F. Optimized protocols for isolation of primary motor neurons, astrocytes and microglia from embryonic mouse spinal cord. J Neurosci Methods 2007; 163: 111-118
59. Mi S, Miller RH, Tang W, Lee X, Hu B, Wu W et al. Promotion of central nervous system remyelination by induced differentiation of oligodendrocyte precursor cells. Ann Neurol 2009; 65: 304-315
60. Shaw G, Yang C, Ellis R, Anderson K, Parker Mickle J, Scheff S et al. Hyperphosphorylated neurofilament NF-H is a serum biomarker of axonal injury. Biochem Biophys Res Commun 2005; 336: 1268-1277